Neurocrine Biosciences (NBIX) Stock Forecast & Price Target

Neurocrine Biosciences is supported by a durable commercial base, with Ingrezza estimated at $2.84B in revenues in 2026 and Crenessity continuing to outperform expectations, including a raised 2026 sales estimate of $750M versus consensus near $650M. Its valuation looks compelling at about a $16B market cap and less than 4x the combined annual sales estimates for Ingrezza and Crenessity, implying limited embedded value for Vykat XR or the pipeline. The outlook is further strengthened by multiple catalysts into 2026+, including expanding TD and CAH penetration, plus several high-upside pipeline readouts in 2027 and 2028 that could add longer-term revenue optionality despite higher clinical risk.

Neurocrine Biosciences is exposed to a fragile earnings profile because its key growth driver, Ingrezza, faces slower-than-expected growth, competitive pressure from Austedo, and possible real-world safety or pricing issues that could erode market share and pricing power. Its newer products, including Crenessity and Vykat XR, are also vulnerable if launch momentum proves temporary or if sales fail to approach the expected ~$1B level, while broader macro pricing pressure and IRA-related competition could further compress revenue. Meanwhile, the pipeline remains heavily concentrated in high-risk CNS assets, so setbacks in efficacy, safety, regulatory approval, or partnerships could leave the company with limited growth levers as Ingrezza approaches LOE in the late 2030s.